FDA
-
-
-
-
-
-
-
Petros Pharmaceuticals (PTPI) Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform
-
-
-
-
-
-
-
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
-
-
-
-
-
-
-
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
-
-
-
-
-
-
-
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
-
-
-
-
-
-
-
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
-
-
-
-
-
-
-
Petros Pharmaceuticals (PTPI) Successfully Launches AI Tool
-
-
-
-
-
-
-
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

